Loss of daptomycin susceptibility in clinical Staphylococcus epidermidis infection coincided with variants in WalK.

Evolution, Medicine, and Public Health
Nicholas F BrazeauLuther A Bartelt

Abstract

Daptomycin (DAP) is key in treating multidrug-resistant Staphylococcus infections. Diminished susceptibility to DAP is emerging among Staphylococcus epidermidis strains although mechanisms for non-susceptibility (NS) remain poorly understood. We report a case of persistent S. epidermidis bacteremia in which loss of DAP susceptibility arose during prolonged treatment. Whole genome sequencing identified two mutations, Q371del and P415L, in a single-affected gene, WalK, that coincided with the emergence of DAP-NS. Protein modeling of the mutations predicted a disruption of WalK protein configuration. The emergence of mutations in a single-gene during DAP exposure raises concerns in an era of increasingly treatment-resistant infections. Lay summary: Daptomycin is an important antibiotic for fighting Staphylococcus infections. We identified variants in the WalK gene that were coincident with resistance in a clinical Staphylococcus epidermidis infection. Clinicians, hospital epidemiologists, and microbiology laboratories need to be aware of the potential for the evolution of drug resistance during prolonged daptomycin therapy.

References

Jul 1, 1982·Infection and Immunity·G D ChristensenE H Beachey
Feb 12, 2005·The Journal of Antimicrobial Chemotherapy·Judith N SteenbergenFrancis P Tally
Apr 13, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A MangiliD H Hamer
Apr 10, 2007·International Journal of Medical Microbiology : IJMM·Andrea JansenGabriele Bierbaum
May 20, 2009·Antimicrobial Agents and Chemotherapy·Philip S StewartJudith N Steenbergen
Feb 20, 2010·Annals of Clinical Microbiology and Antimicrobials·Marylene Duah
Jan 11, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Catherine LiuHenry F Chambers
Mar 30, 2012·The Journal of Infectious Diseases·Rachel J GordonFranklin D Lowy
Dec 12, 2012·Annals of the New York Academy of Sciences·Arnold S BayerHans-Georg Sahl
Sep 5, 2013·Antimicrobial Agents and Chemotherapy·Soo-Jin YangArnold S Bayer
Aug 7, 2014·Trends in Genetics : TIG·Claudio U KöserSharon J Peacock
Sep 17, 2015·Circulation·Larry M BaddourUNKNOWN American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular
Sep 5, 2018·Nature Microbiology·Jean Y H LeeBenjamin P Howden
May 11, 2019·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Sohei HaradaMinoru Ono
Sep 26, 2019·Frontiers in Public Health·Rene S HendriksenPatrick F McDermott

❮ Previous
Next ❯

Methods Mentioned

BETA
electrophoresis

Software Mentioned

PROVEAN

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.